CinFina’s Phase 1 Trials Of CIN-109 & CIN-110 Show Promising Weight Loss Results

CinFina Pharma, part of the CinRx portfolio focusing on developing the most promising next-generation treatments for obesity, said that two Phase 1 clinical trials are showing promising solid results. CIN-110, dosed in a single ascending dose (SAD), and CIN-109, dosed in a multiple ascending dose (MAD),  proved to have good tolerance for the drug candidates and showed meaningful weight loss.

CIN-110 is a novel, long-acting analog of the peptide PYY3-36, designed to reduce gastrointestinal side effects when given subcutaneously. In the interim findings from the SAD study, CIN-110 showed a promising ability to reduce caloric intake and reduce weight.

CinRx Founder and Chief Executive Officer Jon Isaacsohn, M.D., said in a statement, “Despite limitations and side effects, weight loss drugs represent more than $6 billion in annual revenues globally, with projections reaching $150 billion by 2030. The compelling early-stage results from CIN-110 and CIN-109 lead us to believe we can overcome these limitations with next-generation approaches.”

He further commented, “CIN-110’s ability to help safely and tolerably reduce caloric intake while quickly decreasing body weight after just a single dose distinguishes it as a high-potential candidate. Similarly, CIN-109’s significant impact on fat mass reduction and preservation of lean mass, especially at the highest doses, positions it as a powerful long-term solution.”

Among the 24 obese but otherwise healthy participants, body weight decreased by up to 1.8%, and food consumption dropped by as much as 28% within one week of a single dose. CIN-110's formulation gradually raises drug levels in the bloodstream, aiming to limit the typical GI side effects associated with PYY analogs. The peak drug levels were generally reached within two to three days and maintained a half-life of around 14 days. Only mild GI side effects were reported, with cases of nausea resolving within a day.

CIN-109, another long-acting treatment in CinFina's pipeline, acts as a first-in-class analog of growth differentiation factor 15 (GDF-15). The MAD study demonstrated tolerability and dose-dependent weight loss in participants who were given either weekly or biweekly injections. Over one to two months, food intake reductions of up to 50% were observed, leading to weight loss of up to 3.7%. Those treated with CIN-109 every other week appeared to tolerate it better, as no significant side effects were reported. Most of the weight loss was due to fat mass, so CIN-109 can be considered an agent for treating obesity.